Our lead drug candidate, WBI-1001, is targeted as a topical cream treatment for psoriasis, a chronic autoimmune skin disease.

Currently there is no cure for psoriasis which is a disease that affects millions of people worldwide. Many of the current therapies have unwanted side effects and show a slow response. As well, the so called “biologics” that are administered by medical injections are frequently very high cost treatments.

Welichem’s WBI-1001 drug candidate, now in formal preclinical trials, is applied as a cream to affected areas. Its market advantage is that it is a treatment that targets the cause of this disease, rather than only alleviating the symptoms. It selectively modulates the cytokine cascade deep under the skin, a process that rapidly decreases inflammations and skin plague.

Conclusion of the formal preclinical trials will enable this drug to be considered by the regulatory authorities in Canada and the USA for initiation of clinical trials.